Trial Profile
A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms RAISE
- 08 Feb 2024 Status changed from not yet recruiting to recruiting.
- 17 Jan 2024 Planned initiation date changed from 1 Dec 2023 to 1 Mar 2024.
- 17 Oct 2023 Planned initiation date changed from 1 Oct 2023 to 1 Dec 2023.